Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19 and are especially important in high-risk individuals where vaccination is not an option …
J Tang, C Zeng, TM Cox, C Li, YM Son, IS Cheon… - Science …, 2022 - science.org
SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the circulation; however, it is currently unknown whether it elicits effective immune responses in …
The emergence of the SARS-CoV-2 variant of concern Omicron (Pango lineage B. 1.1. 529), first identified in Botswana and South Africa, may compromise vaccine effectiveness and …
JJ Lau, SMS Cheng, K Leung, CK Lee, A Hachim… - Nature medicine, 2023 - nature.com
Abstract The SARS-CoV-2 Omicron variant has demonstrated enhanced transmissibility and escape of vaccine-derived immunity. Although first-generation vaccines remain effective …
Abstract The B. 1.1. 529/Omicron variant of SARS-CoV-2 was only recently detected in southern Africa, but its subsequent spread has been extensive, both regionally and globally …
Recent surveillance has revealed the emergence of the SARS-CoV-2 Omicron variant (BA. 1/B. 1.1. 529) harboring up to 36 mutations in spike protein, the target of neutralizing …
The Omicron variant of SARS-CoV-2 infected many vaccinated and convalescent individuals,–. Despite the reduced protection from infection, individuals who received three …
The Omicron variant is rapidly becoming the dominant SARS-CoV-2 virus circulating globally. It is important to define reductions in virus neutralizing activity in the serum of …
RL Atmar, KE Lyke, ME Deming… - … England Journal of …, 2022 - Mass Medical Soc
Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in the United States are highly effective …